Economic Burden of Sanfilippo Syndrome in the United States
暂无分享,去创建一个
[1] R. Giugliani,et al. Sanfilippo syndrome: consensus guidelines for clinical care , 2022, Orphanet Journal of Rare Diseases.
[2] J. Mellerio. The challenges of clinical trials in rare diseases , 2022, The British journal of dermatology.
[3] J. Hinkel,et al. The economics of moonshots: Value in rare disease drug development , 2022, Clinical and translational science.
[4] H. Rehm. Time to make rare disease diagnosis accessible to all , 2022, Nature Medicine.
[5] R. Rubin. The Cost of Rare Diseases. , 2021, Journal of the American Medical Association (JAMA).
[6] Shanshan Wu,et al. Global epidemiology of mucopolysaccharidosis type III (Sanfilippo syndrome): an updated systematic review and meta-analysis , 2021, Journal of pediatric endocrinology & metabolism : JPEM.
[7] L. Lynd,et al. Toward the diagnosis of rare childhood genetic diseases: what do parents value most? , 2021, European Journal of Human Genetics.
[8] A. Nahvijou,et al. Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds , 2021, Cost Effectiveness and Resource Allocation.
[9] J. Baruteau,et al. Novel therapies for mucopolysaccharidosis type III , 2020, Journal of inherited metabolic disease.
[10] Emily P. Terlizzi,et al. Symptoms of Generalized Anxiety Disorder Among Adults: United States, 2019. , 2020, NCHS data brief.
[11] C. Murray,et al. Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study , 2020, The Lancet.
[12] M. Iacovino,et al. A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise. , 2020, Medical research archives.
[13] Florence T. Bourgeois,et al. Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis , 2019, PLoS medicine.
[14] K. Romero,et al. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders , 2019, Orphanet Journal of Rare Diseases.
[15] D. Brody,et al. Prevalence of Depression Among Adults Aged 20 and Over: United States, 2013-2016. , 2018, NCHS data brief.
[16] F. Wijburg,et al. Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications , 2018, Orphanet Journal of Rare Diseases.
[17] C. Lourenço,et al. Epilepsy in mucopolysaccharidosis disorders. , 2017, Molecular genetics and metabolism.
[18] S. Jones,et al. Practical management of behavioral problems in mucopolysaccharidoses disorders. , 2017, Molecular genetics and metabolism.
[19] A. Shaywitz,et al. Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III , 2017, Orphanet Journal of Rare Diseases.
[20] T. Trikalinos,et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.
[21] H. Boshuizen,et al. Accounting for multimorbidity can affect the estimation of the Burden of Disease: a comparison of approaches , 2016, Archives of Public Health.
[22] C. Tudur Smith,et al. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov , 2014, Orphanet Journal of Rare Diseases.
[23] C. Heldermon,et al. Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies. , 2014, Pediatric endocrinology reviews : PER.
[24] R. Giugliani,et al. The laboratory diagnosis of mucopolysaccharidosis III (Sanfilippo syndrome): A changing landscape. , 2014, Molecular genetics and metabolism.
[25] E. Cantone,et al. Management of otolaryngological manifestations in mucopolysaccharidoses: our experience , 2013, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.
[26] P. Hogan,et al. Economic Costs of Diabetes in the U , 2013 .
[27] B. Burton,et al. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder , 2013, Acta paediatrica.
[28] Alan D. Lopez,et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[29] Rolf H H Groenwold,et al. Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression , 2012, Canadian Medical Association Journal.
[30] M. Grootenhuis,et al. Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome) , 2011, Orphanet journal of rare diseases.
[31] D. Scherman,et al. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. , 2011, Molecular genetics and metabolism.
[32] D. Zafeiriou,et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece , 2011, American journal of medical genetics. Part A.
[33] R. Wevers,et al. Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlations , 2010, Annals of neurology.
[34] R. Wevers,et al. Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype , 2010, Journal of Inherited Metabolic Disease.
[35] A. Pshezhetsky,et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. , 2008, Molecular genetics and metabolism.
[36] Olga V. Demler,et al. The US National Comorbidity Survey Replication (NCS‐R): design and field procedures , 2004, International journal of methods in psychiatric research.
[37] M. Delatycki,et al. Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians , 2002, Clinical genetics.
[38] P. Meikle,et al. Prevalence of lysosomal storage disorders. , 1999, JAMA.
[39] J. Zhang,et al. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.
[40] J. Deeks. When can odds ratios mislead? , 1998 .
[41] M. Bax,et al. Behaviour in mucopolysaccharide disorders. , 1995, Archives of disease in childhood.
[42] J. E. Wraith,et al. Management of mucopolysaccharidosis type III. , 1993 .
[43] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[44] L. Haverman,et al. Psychosocial Functioning in Parents of MPS III Patients. , 2019, JIMD reports.
[45] Y. Puckett,et al. Epidemiology of mucopolysaccharidoses (MPS) in the United States: challenges and opportunities , 2017 .
[46] Archives of Stem Cell and Therapy , 2022 .